covalent closed-loop structure, anti nucleases, which means low production and storage costs, long half-life, and long efficacy
No need 5'Cap, 3'poly A, and N1-Methyl-Pseudouridine
Impossible integrate into the genome
Low/no immunogenicity in vivo, and good for long-term multiple administration
Creating a new class of therapeutics requires thinking outside the lines. Comprised of a team of skilled scientists, molecular engineers, and industry veterans in addition to a world class Board, we are well-suited for the challenge of bringing the promise of our oRNATM therapeutics to patients.
■ 20+ years experience in biologics focusing on protein drugs, genetic drugs and vaccines
■ Led application and approval of 5 successful IND approvals & 3 phase I clinical studies
■ Rich in-licensing & out- licensing experiences
■ Filed 12 patents & published 16 papers
■ Ph.D. of ICCAS, Postdoc at MSU
■ 20+ years research in RNA and CircRNA
■ 70+ publications (13 with IF≥PNAS)
■ 2 of 4 Circ RNA were discovered by Shan’ s Lab up-to-date in the world
■ Discovery of a new class of CircRNAs, EIciRNAs
■ NSMB IF = 15.369,citations >2300
■ PhD of Georgia State University, Postdoc at Emory and Yale Universities
■ Postdoc mentor: Dr. Sidney Altman, Nobel Prize in Chemistry 1989 for the discovery of Ribozyme